Search research articles
Contact Us
Filters
Showing results (501-510 of 522) with videos related to
Page
of 53
Sort By:
ESMO Open
|
October 12, 2024
Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial
E Scanlon, A Lavery, M Albraikat, et al.
Nature Medicine
|
December 16, 2022
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma
Chelsea A Taylor, Robert A Watson, Orion Tong, et al.
Nature Communications
|
February 19, 2021
Tumour gene expression signature in primary melanoma predicts long-term outcomes
Manik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, et al.
Developmental Cell
|
September 16, 2021
Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation
Nathaniel R Campbell, Anjali Rao, Miranda V Hunter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H I Andtbacka, Howard L Kaufman, Frances Collichio, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
James Larkin, Jeffrey Weber, Michele Del Vecchio, et al.
BMC Cancer
|
April 11, 2025
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)
Francesca Aroldi, Elena Elez, Thierry André, et al.
The Lancet. Oncology
|
September 22, 2020
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A Ascierto, Michele Del Vecchio, Mario Mandalá, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 2, 2020
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention
Alexander J Stratigos, Claus Garbe, Clio Dessinioti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2024
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma
Omid Hamid, Karl D Lewis, Amy Weise, et al.
Page
of 53
Search research articles
Search
Showing results (501-510 of 522) with videos related to
Sort By:
Page
of 53
ESMO Open
|
October 12, 2024
Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial
E Scanlon, A Lavery, M Albraikat, et al.
Nature Medicine
|
December 16, 2022
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma
Chelsea A Taylor, Robert A Watson, Orion Tong, et al.
Nature Communications
|
February 19, 2021
Tumour gene expression signature in primary melanoma predicts long-term outcomes
Manik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, et al.
Developmental Cell
|
September 16, 2021
Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation
Nathaniel R Campbell, Anjali Rao, Miranda V Hunter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H I Andtbacka, Howard L Kaufman, Frances Collichio, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
James Larkin, Jeffrey Weber, Michele Del Vecchio, et al.
BMC Cancer
|
April 11, 2025
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)
Francesca Aroldi, Elena Elez, Thierry André, et al.
The Lancet. Oncology
|
September 22, 2020
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A Ascierto, Michele Del Vecchio, Mario Mandalá, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 2, 2020
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention
Alexander J Stratigos, Claus Garbe, Clio Dessinioti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2024
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma
Omid Hamid, Karl D Lewis, Amy Weise, et al.
Page
of 53